Wendy's could now assure customers of the availability of its burgers and other beef products as it announced that its beef supply is back to "near-normal levels.'
The fast-food chain experienced disruptions to its beef supply amid the pandemic. Through May, it was forced to temporarily take off beef from the menu at 18 percent of its restaurants across the United States.
The Dublin, Ohio-based Wendy's had to promote chicken-based dishes for the time being to alleviate pressure on beef demand while working with supply chain partners to deliver beef to "all Wendy's system restaurants" two or three times a week.
Famous for its "fresh, never frozen" burgers, the absence of its flagship product had customers asking, "where's the beef?"
As of May 31, 99 percent of the food chain's 5,861 locations in the US have opened for business.


OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 



